Do analysts rate AIKI or PLUT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Plutus Financial Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, AIKI or PLUT?

Plutus Financial Group has higher revenue and earnings than AIkido Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AIkido Pharma N/A N/A -$7.17M -$3.88 N/A Plutus Financial Group $1.34M 28.47 -$5.06M N/A N/A

Is AIKI or PLUT more profitable?

Plutus Financial Group's return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets AIkido Pharma N/A -18.21% -16.94% Plutus Financial Group N/A N/A N/A

Do analysts rate MDBH or AIKI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MDB Capital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is MDBH or AIKI more profitable?

AIkido Pharma's return on equity of -18.21% beat MDB Capital's return on equity. Company Net Margins Return on Equity Return on Assets MDB Capital N/A -39.77% -38.48% AIkido Pharma N/A -18.21% -16.94%

Do analysts recommend GRAN or AIKI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grande Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, GRAN or AIKI?

Grande Group has higher revenue and earnings than AIkido Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grande Group $1.81M 14.04 -$3.47M N/A N/A AIkido Pharma N/A N/A -$7.17M -$3.88 N/A

Is GRAN or AIKI more profitable?

Grande Group's return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Grande Group N/A N/A N/A AIkido Pharma N/A -18.21% -16.94%

Do analysts prefer AIKI or BCG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Binah Capital Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer GSIW or AIKI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Garden Stage 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, GSIW or AIKI?

AIkido Pharma has lower revenue, but higher earnings than Garden Stage. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Garden Stage $7.28M 2.87 -$13.84M N/A N/A AIkido Pharma N/A N/A -$7.17M -$3.88 N/A

Is GSIW or AIKI more profitable?

Garden Stage's return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Garden Stage N/A N/A N/A AIkido Pharma N/A -18.21% -16.94%

AIkido Pharma (AIKI) Competitors

$2.23 +0.05 (+2.29%)

As of 09/14/2026

Compare

AIKI vs. PLUT, MDBH, GRAN, BCG, and GSIW

Should you buy AIkido Pharma stock or one of its competitors? AIkido Pharma's main competitors and comparable companies include Plutus Financial Group (PLUT), MDB Capital (MDBH), Grande Group (GRAN), Binah Capital Group (BCG), and Garden Stage (GSIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "investment banking & brokerage" industry.

How does AIkido Pharma compare to Plutus Financial Group?

AIkido Pharma (NASDAQ:AIKI) and Plutus Financial Group (NASDAQ:PLUT) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

10.9% of AIkido Pharma shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Plutus Financial Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

AIkido Pharma has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Plutus Financial Group has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

In the previous week, Plutus Financial Group had 2 more articles in the media than AIkido Pharma. MarketBeat recorded 2 mentions for Plutus Financial Group and 0 mentions for AIkido Pharma. Plutus Financial Group's average media sentiment score of 1.31 beat AIkido Pharma's score of 0.00 indicating that Plutus Financial Group is being referred to more favorably in the news media.

Company	Overall Sentiment
AIkido Pharma	Neutral
Plutus Financial Group	Positive

Plutus Financial Group has higher revenue and earnings than AIkido Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Plutus Financial Group	$1.34M	28.47	-$5.06M	N/A	N/A

Plutus Financial Group's return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Plutus Financial Group	N/A	N/A	N/A

Summary

Plutus Financial Group beats AIkido Pharma on 8 of the 10 factors compared between the two stocks.

How does AIkido Pharma compare to MDB Capital?

MDB Capital (NASDAQ:MDBH) and AIkido Pharma (NASDAQ:AIKI) are both small-cap finance companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDB Capital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.4% of MDB Capital shares are owned by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are owned by institutional investors. 55.8% of MDB Capital shares are owned by insiders. Comparatively, 8.6% of AIkido Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MDB Capital has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, AIkido Pharma has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

In the previous week, MDB Capital had 2 more articles in the media than AIkido Pharma. MarketBeat recorded 2 mentions for MDB Capital and 0 mentions for AIkido Pharma. MDB Capital's average media sentiment score of 0.62 beat AIkido Pharma's score of 0.00 indicating that MDB Capital is being referred to more favorably in the media.

Company	Overall Sentiment
MDB Capital	Positive
AIkido Pharma	Neutral

AIkido Pharma's return on equity of -18.21% beat MDB Capital's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDB Capital	N/A	-39.77%	-38.48%
AIkido Pharma	N/A	-18.21%	-16.94%

AIkido Pharma has lower revenue, but higher earnings than MDB Capital. MDB Capital is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDB Capital	$4.91M	5.80	-$21.25M	-$2.18	N/A
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A

Summary

MDB Capital beats AIkido Pharma on 7 of the 12 factors compared between the two stocks.

How does AIkido Pharma compare to Grande Group?

Grande Group (NASDAQ:GRAN) and AIkido Pharma (NASDAQ:AIKI) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Grande Group has higher revenue and earnings than AIkido Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grande Group	$1.81M	14.04	-$3.47M	N/A	N/A
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A

In the previous week, Grande Group had 1 more articles in the media than AIkido Pharma. MarketBeat recorded 1 mentions for Grande Group and 0 mentions for AIkido Pharma. Grande Group's average media sentiment score of 1.89 beat AIkido Pharma's score of 0.00 indicating that Grande Group is being referred to more favorably in the media.

Company	Overall Sentiment
Grande Group	Very Positive
AIkido Pharma	Neutral

Grande Group's return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grande Group	N/A	N/A	N/A
AIkido Pharma	N/A	-18.21%	-16.94%

10.9% of AIkido Pharma shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grande Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Grande Group beats AIkido Pharma on 7 of the 9 factors compared between the two stocks.

How does AIkido Pharma compare to Binah Capital Group?

AIkido Pharma (NASDAQ:AIKI) and Binah Capital Group (NASDAQ:BCG) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Binah Capital Group has a net margin of 2.17% compared to AIkido Pharma's net margin of 0.00%. Binah Capital Group's return on equity of 195.38% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Binah Capital Group	2.17%	195.38%	5.95%

AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Binah Capital Group has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

10.9% of AIkido Pharma shares are owned by institutional investors. Comparatively, 5.0% of Binah Capital Group shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by insiders. Comparatively, 7.8% of Binah Capital Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Binah Capital Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Binah Capital Group has higher revenue and earnings than AIkido Pharma. AIkido Pharma is trading at a lower price-to-earnings ratio than Binah Capital Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Binah Capital Group	$185.84M	0.11	$2.31M	$0.18	6.94

In the previous week, Binah Capital Group had 2 more articles in the media than AIkido Pharma. MarketBeat recorded 2 mentions for Binah Capital Group and 0 mentions for AIkido Pharma. Binah Capital Group's average media sentiment score of 1.30 beat AIkido Pharma's score of 0.00 indicating that Binah Capital Group is being referred to more favorably in the news media.

Company	Overall Sentiment
AIkido Pharma	Neutral
Binah Capital Group	Positive

Summary

Binah Capital Group beats AIkido Pharma on 10 of the 13 factors compared between the two stocks.

How does AIkido Pharma compare to Garden Stage?

Garden Stage (NASDAQ:GSIW) and AIkido Pharma (NASDAQ:AIKI) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, Garden Stage had 1 more articles in the media than AIkido Pharma. MarketBeat recorded 1 mentions for Garden Stage and 0 mentions for AIkido Pharma. Garden Stage's average media sentiment score of 0.67 beat AIkido Pharma's score of 0.00 indicating that Garden Stage is being referred to more favorably in the media.

Company	Overall Sentiment
Garden Stage	Positive
AIkido Pharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Garden Stage	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Garden Stage has a beta of 3.95, indicating that its stock price is 295% more volatile than the broader market. Comparatively, AIkido Pharma has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Garden Stage's return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Garden Stage	N/A	N/A	N/A
AIkido Pharma	N/A	-18.21%	-16.94%

AIkido Pharma has lower revenue, but higher earnings than Garden Stage.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Garden Stage	$7.28M	2.87	-$13.84M	N/A	N/A
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A

0.5% of Garden Stage shares are owned by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Garden Stage beats AIkido Pharma on 7 of the 10 factors compared between the two stocks.

Get AIkido Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIKI vs. The Competition

Export

Metric	AIkido Pharma	Capital Markets Industry	Finance Sector	NASDAQ Exchange
Market Cap	$12.23M	$5.27B	$13.78B	$14.89B
Dividend Yield	N/A	7.50%	5.95%	11.71%
P/E Ratio	-0.57	29.96	25.26	25.33
Price / Sales	N/A	1,168.46	497.16	112.26
Price / Cash	N/A	47.91	40.57	51.48
Price / Book	0.12	3.50	2.72	6.24
Net Income	-$7.17M	$417.39M	$1.31B	$358.55M
7 Day Performance	10.40%	-1.36%	-0.95%	-2.03%
1 Month Performance	-17.71%	-2.92%	-1.31%	-4.78%
1 Year Performance	-62.39%	3.87%	9.54%	5.46%

AIkido Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIKI AIkido Pharma	N/A	$2.23 +2.3%	N/A	-66.0%	$12.23M	N/A	N/A	4	Gap Up High Trading Volume
PLUT Plutus Financial Group	0.7813 of 5 stars	$2.55 -3.7%	N/A	-22.8%	$39.16M	$1.34M	N/A	10	Positive News Gap Down
MDBH MDB Capital	0.4539 of 5 stars	$2.82 +0.7%	N/A	-28.1%	$29.05M	$4.91M	N/A	40
GRAN Grande Group	0.7255 of 5 stars	$1.08 +8.0%	N/A	-74.8%	$26.59M	$1.81M	N/A	20	Gap Down High Trading Volume
BCG Binah Capital Group	2.0022 of 5 stars	$1.26 -0.7%	N/A	-13.1%	$21.50M	$185.84M	7.00	130	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIKI) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AIkido Pharma (AIKI) Competitors

AIKI vs. PLUT, MDBH, GRAN, BCG, and GSIW

How does AIkido Pharma compare to Plutus Financial Group?

Summary

How does AIkido Pharma compare to MDB Capital?

Summary

How does AIkido Pharma compare to Grande Group?

Summary

How does AIkido Pharma compare to Binah Capital Group?

Summary

How does AIkido Pharma compare to Garden Stage?

Summary

Media Sentiment Over Time

AIKI vs. The Competition

AIkido Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AIkido Pharma (AIKI) Competitors

AIKI vs. PLUT, MDBH, GRAN, BCG, and GSIW

How does AIkido Pharma compare to Plutus Financial Group?

Do institutionals and insiders believe in AIKI or PLUT?

Do analysts rate AIKI or PLUT?

Which has more volatility and risk, AIKI or PLUT?

Does the media favor AIKI or PLUT?

Which has higher earnings and valuation, AIKI or PLUT?

Is AIKI or PLUT more profitable?

Summary

How does AIkido Pharma compare to MDB Capital?

Do analysts rate MDBH or AIKI?

Do institutionals & insiders hold more shares of MDBH or AIKI?

Which has more volatility & risk, MDBH or AIKI?

Does the media prefer MDBH or AIKI?

Is MDBH or AIKI more profitable?

Which has better earnings and valuation, MDBH or AIKI?

Summary

How does AIkido Pharma compare to Grande Group?

Which has better valuation & earnings, GRAN or AIKI?

Does the media favor GRAN or AIKI?

Is GRAN or AIKI more profitable?

Do insiders & institutionals hold more shares of GRAN or AIKI?

Do analysts recommend GRAN or AIKI?

Summary

How does AIkido Pharma compare to Binah Capital Group?

Is AIKI or BCG more profitable?

Which has more volatility and risk, AIKI or BCG?

Do insiders & institutionals have more ownership in AIKI or BCG?

Do analysts prefer AIKI or BCG?

Which has higher earnings and valuation, AIKI or BCG?

Does the media favor AIKI or BCG?

Summary

How does AIkido Pharma compare to Garden Stage?

Does the media prefer GSIW or AIKI?

Do analysts prefer GSIW or AIKI?

Which has more volatility & risk, GSIW or AIKI?

Is GSIW or AIKI more profitable?

Which has better valuation and earnings, GSIW or AIKI?

Do insiders and institutionals have more ownership in GSIW or AIKI?

Summary

Media Sentiment Over Time

AIKI vs. The Competition

AIkido Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools